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We have  found that  complement  is activated  during blood coagulation  (1).  This 
activation  was  characterized  by  the  development  of ultrastructural  lesions  on  the 
platelet surface subsequent  to physiologic clotting. The appearance of the lesions was 
dependent  on  the  presence  of thrombin  and  of C3.  In  further  studies,  the  role  of 
complement  in  thrombin-mediated  platelet  function  was  investigated  (2,  3).  It was 
found  that  thrombin-mediated  platelet  aggregation  and  release  of serotonin  was 
significantly enhanced in the presence of complement. Only complement components 
C3, C5,  C6, C7, C8,  and C9 were required  for this  reactivity.  No known activating 
mechanism of either the classical pathway or alternative pathway was required. Thus, 
a  new  pathway  of activation  of complement  was  described--one  which  required 
thrombin,  the platelet  surface,  and entered  the known complement sequence at  the 
C3 stage. Activation of this pathway led to the production of C5b-9 complexes that 
were visualized  as typical  lesion  formation on the platelet  surface  (3).  During these 
studies  it  was  shown  that  the  complement  effect  was  inhibited  by  aspirin  and 
indomethacin,  drugs  known to inhibit  platelet  cyclooxygenase. Thus  the  possibility 
existed  that  the  complement  effect  might  be  mediated  via  the  arachidonic  acid 
transformation  pathway with production of thromboxane A2. 
The purpose of this study was to elucidate the role of complement in the arachidonic 
acid transformation  pathway in platelets. 
Materials  and Methods 
Preparation of Washed Platelets and Platelet Membranes.  A suspension of human platelets was 
obtained using the Ardlie buffer system modified as previously described  (2). Platelet  mem- 
branes were prepared according to a published method (4). 
Preparation of Complement Components.  C3 (5), C4 (6), C5 (7), C6, C7 (8), C8 (9), and C9 (10) 
were  prepared  by  methods  described  earlier.  In  addition,  in  some  experiments,  purified 
complement  components  prepared  by Cordis  Laboratories  Inc.,  Miami,  Fla.  were  utilized. 
Before use, the complement components were dialyzed overnight against cacodylate buffer, pH 
7.4 (2). 
Radiolabeling of the  Third  (C3)  and Fifth  (C5)  Components of Complement.  C3  and  C5 were 
•  125  labeled with  I by the method of McConahey and Dixon (11). The specific  activity of each 
component was ~100,000 cpm/~g. 
Platelet Aggregation.  Assays for platelct aggregation were performed in a Payton dual channel 
aggregometer equipped with a Riken Denshi recorder (Payton Associates,  Inc., Buffalo, N. Y.). 
Washed platelets were suspended at  200,000//~1 in Ardlie II buffer in which bicarbonate was 
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replaced with Tris (2). Sodium arachidonate (Nuchek Prep., Inc., Elysian, Minn.) at various 
concentrations in 10-/~1 vol was added to 0.3 ml platelets. The sodium arachidonate used in 
these  experiments was prepared under nitrogen. The platelet mixtures were stirred for 5 min 
while aggregation responses  were recorded, and samples then were taken for release  measure- 
ments. The sodium salt of both oleic and linoleic acid (Sigma Chemical Co., St.  Louis, Mo.) 
were also utilized. 
Release of[t4C]Serotonin.  Platelets suspended in plasma were labeled with [14C]serotonin by 
the  method  of  Valdorf-Hansen  and  Zucker  (12). The  radiolabeled  platelets  were  then 
washed in the usual way (2, 3). For the experiment, aliquots of various reagents were added to 
0.3  ml of the washed platelet suspension. Aggregation was recorded for 5 min, and then the 
tube was rapidly centrifuged and the supernate removed. 14C was counted in both the supernate 
and the cell button in a  Packard liquid scintillation counter (Packard Instrument Co.,  Inc., 
Downers Grove, Ill.) and the percentate of release was calculated. 
Release of Lactic  Dehydrogenase (LDH). 1  LDH  release  was  determined by the  method of 
Wroblewski and La Due (13). 1 U was expressed  as decrease  in OD at 340/~m of 0.001/min per 
ml. A control sample giving 100% lysis was obtained by the addition of 0.1% Triton X-100. 
Assay for Thromboxane B~ (TXB2).  The amounts of thromboxane A2 (TXA2) released  by the 
platelet suspensions during stimulation with aggregating agents in the presence and absence of 
complement components were measured by radioimmunoassay  for TXB2, the stable metabolite 
of TXA2. Conversion to this metabolite was accomplished by permitting the platelet supernates 
to remain in aqueous solution. The radioimmunoassay  for TXB2 was developed using antibodies 
produced  in rabbits  to  a  carbodiimide conjugate of synthetic TXB2  with  keyhole  limpet 
hemoeyanin. Details of this assay will be presented elsewhere.  (R.  Levin, B. B. Weksler, K. 
Tack-Goldman, and  E.  A.  Jaffe.  Manuscript  in  preparation.)  Briefly,  100  #1  of  platelet 
supernate, 100 p.1 of anti-TXB2 antiserum (1:4,800) and 100/~1 of [SH]TXB2 (150 Ci/mmol sp 
act;  10,000 dpm;  New  England Nuclear,  Boston,  Mass.)  were  incubated together at  room 
temperature for 18 h. Separation was accomplished by addition of 100 #1 protein A-containing 
staphylococci (Pansorbin; 1:10 dilution; Calbiochem-Behring  Corp., American Hoechst Corp., 
San Diego,  Calif.) and liquid scintillation counting of an aliquot of supernate after centrifu- 
gation of the precipitated antigen-antibody  complexes.  Assay data were analyzed by the four 
parametric method of Rodbard. The range of sensitivity for TXB2 was 3-1,000 pg, with a 
midpoint of 30-40 pg. Duplicate samples were assayed at two or three dilutions. 
Uptake oft~I-C3 and 1~I-C5 by Platelet Membranes.  Platelet membranes prepared as described 
previously (4) were divided into four 1-ml aliquots. To the first aliquot was added 50 CHs0 U 
(CH~ U, the amount of any complement required to produce 50% lysis of antibody-sensitized 
sheep cells) each of C5, C6, C7, C8, and C9 and 125I-C3 (60/~g containing 4.2 x  106 cpm). To 
the second aliquot was added 50 CHs0 U of each C3, C6, C7, C8, and C9 and 125I-C5 (10 p.g 
containing 2  ×  l0  s  cpm).  Sodium  arachidonate  was  added  to  both  aliquots  at  a  final 
concentration of 100 ~tM. Aliquots 3 and 4 contained the same complement components as did 
1 and 2, but did not contain sodium arachidonate. The mixtures were incubated at 37°C for 
1 h, and then after an extensive washing procedure, the radioactivity in the membrane pellet 
was  determined.  The  platelet  membranes were  dissolved  in  1 N  NaOH  and  the  protein 
concentration was determined. 
Preparation of F(ab')2 Fragments of Antisera.  The y-globulin fractions were  prepared  from 
monospecific antiserum to C3, C4, C5, C6, and C9, and human serum albumin prepared in 
rabbits  and  goat  anti-rabbit  y-globulin by  ammonium sulfate  precipitation  followed  by 
triethylaminoethyl-cellulose  column chromatography with phosphate buffer, pH  8.0, 0.0175 
M. The purified y-globulin preparations were digested with pepsin at various concentrations 
from 0.1 to 1% by the method of Nisonoff et al.  (14). Antibody activity of the digested protein 
was tested by Ouchterlony analysis and degree of digestion was determined by sodium dodecyl 
sulfate-polyacrylamide  gel electrophoresis.  It was found with each antibody that digestion with 
0.4% pepsin yielded a totally digested protein which retained full antibody activity. 
Ferritin Conjugation of Goat Anti-Rabbit y-Globulin Serum.  The F(ab')2 fragment of the goat anti- 
l Abbreviations used in this paper." CHs0 U, the amount of any complement component required to produce 
50%  lysis of antibody-sensitized sheep cells. DOC, deoxycholate; LDH, lactic dehydrogenase; TXA2, 
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rabbit y-globulin serum was conjugated with ferritin by the method of Tawde and Ram (15). 
Free  ferritin  and  unconjugated  y-globulin were  separated  from  conjugated  y-globulin by 
Pevikon (Mercer Consolidated Corp., Yonkers, N. Y.) block eleetrophoresis (16). 
Localization of Arachidonate-mediated Platelet-bound  C3 and C5 by Electron Microscopy.  200 CHs0 U 
each of C3, C5, C6, C7, C8, and C9 and sodium arachidonate at a final concentration of 100 
/tM were added to 15 ml washed platelet suspension at 200,000/#1.  The mixture was placed on 
a  rotator for 20  min  at  37°C.  The  platelets were washed  three  times with saline and  then 
divided into three equal aliquots of 1 ml. To the first aliquot was added 0.3 ml of the F(ab')~ 
fraction of anti-C3;  to  the second aliquot, the similar fraction of anti-C5;  and  to the third 
aliquot saline was added. The mixtures were incubated at 37°C for 1 h with occasional mixing. 
After three washes with saline, 0.2 ml of ferritin-conjugatedF(ab')~ fragment of goat anti-rabbit 
y-globulin was added to the resuspended platelets. These mixtures were incubated at 37°C for 
1 h with occasional mixing. The platelets were washed three times in saline and after the last 
wash were resuspended in 0.5 ml water. The platelets were then lysed by freezing and thawing 
three times. The resultant platelet pellet was washed twice with saline diluted 1  : 10 and buffered 
to pH  6.5,  then  applied unstained to a  copper grid coated with collodion and  carbon  and 
viewed under a Philips 301 electron microscope (Philips Electronic Instruments, Inc., Mahwah, 
N.J.) at 80 kv. 
Preparation of Arachidonate-mediated Platelet Membrane-bound C5b-9 Complexes.  Platelet  mem- 
branes from 9 U of blood were utilized (4).  1 ml modified Ardlie II buffer (2) was added to the 
membrane button. The membranes were thoroughly mixed and 0.25  ml was aliquoted into 
each of two tubes. 4.75  ml of the same buffer was added to both tubes. To the first tube was 
added 90#g C5 (4.0 ×  107 cpm) and 400 CHso units of each C6, C7, C8, and C9, followed by 
sodium arachidonate at a  final concentration of 100/tM.  The second aliquot contained the 
same amount of complement components but no arachidonate. Both tubes were clipped onto 
a rotator and incubated for 30 rain at 37°C. The same method was utilized to elute the putative 
C5b-9 complexes as was previously described (3). Briefly, the complexes were eluted with 10% 
deoxycholate (DOC) (Sigma Chemical Co.). The eluate was applied to a Bio-Gel A15m column 
(Bio-Rad Laboratories, Richmond, Calif.). The first peak of protein to elute from this column 
was subjected to sucrose density gradient ultracentrifugation. The material obtained from the 
gradient with a sedimentation coefficient of 33S was processed for electron microscopy (3) and 
viewed in a Philips 301  electron microscope. 
Results 
Effect of Complement on Sodium Arachidonate-mediated Release of [14C]Serotonin.  Table I 
shows the results of 10 experiments in which sodium arachidonate-mediated release 
of 14C-serotonin from washed platelets was measured in the presence and absence of 
complement. In every experiment, addition of complement components C5, C6, C7, 
C8,  and C9 led to an  increase in the percent  release of serotonin. 4  CH~0 U  of each 
component  were found  to be optimal in augmenting serotonin release. The concen- 
trations of sodium arachidonate employed were 30-70/IM  and  in this range, <10% 
platelet lysis resulted. The degree of enhancement  of serotonin release varied from 46 
to 554% (P <  0.001). The factors influencing the variability of the response in different 
platelet preparations was not determined. All five components, C5, C6, C7, C8, and 
C9, were required for an optimal enhancement  effect. Experiments were performed 
using C5 alone, C5, C6, and C7 alone, and C8 and C9 alone. Under these conditions, 
suboptimal enhancement  of serotonin release was obtained. This pattern was similar 
to that observed in our previous studies with thrombin (2). In no case did addition of 
C5-C9 lead to an increase in platelet lysis. Pretreatment of platelets with aspirin (100 
I~M) totally inhibited the arachidonate-mediated serotonin release both in the absence 
and  presence of complement.  Addition  of C~-C9  induced  no  enhancement  of 14C 260  COMPLEMENT  AND ARACHIDONIC  ACID TRANSFORMATION 
TABLE  I 
Arachidonic Acid-mediated Release of /l~Cf Serotonin in the Presence  and 
Absence of Complement 
Percent release of serotonin 
Experiment  Arachidonic  Arachidonic acid  Percent  enhancement 
acid* alone  plus C5-95 
l  31  52  67.7 
2  22  69  213.6 
3  35  79  125.7 
4  11  32  190.0 
5  12  35  191.6 
6  32  47  46.8 
7  44  88  100.0 
8  16  28  75.0 
9  11  71  554.5 
10  26  44  69 
* Concentration of arachidonic acid varied from 30 to 70 #M. 
:[: 4 CH~o U each of C5, C6, C7, C8, and C9. 
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Fro.  1.  Effect of purified complement components on arachidonate-mediated release of [14C]- 
serotonin. A.A.: sodium arachidonate (50 ~M); C3-9: complement components C3, C5, C6, C7, C8, 
and C9; C5-9: complement components C5, C6, C7, C8 and C9;  1 and 2 indicate sequence of 
addition. 
serotonin release mediated by either oleic or linoleic acid (in the dose range of 70-120 
~M). 
Because complement components C3-C9 are required for enhancement of throm- 
bin-mediated platelet release of serotonin, experiments were performed to determine 
whether addition of C3 might increase the release obtained with C5-C9. As indicated 
in Fig.  1, no increment in serotonin release was obtained when C3 was added to the 
C5-9 mixture. Because it has been shown (2) that complement proteins are present on 
the  platelet  surface,  the  possibility arose  whether  membrane-bound C3  might  be 
participating in the  complement-mediated reaction in the  absence of exogenously 
added C3. To answer this question, platelets were incubated with the F(ab')2 fraction 
of anti-C3 before exposure to sodium arachidonate and C5-C9. As shown in Fig. 2, 
incubation of platelets with anti-C3 did  not  inhibit serotonin release mediated by 
C5-C9. 
As was  the case with  the complement-dependent enhancement of thrombin-me- 
diated platelet function, no known activating mechanism of the classical or alternative 60 ! 
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FIG. 2.  Effect of anti-C3  on arachidonate-mediated release of [14C]serotonin  in  the presence of 
C5-9. Anti-C3:F(ab')2 fragments of anti-C3. A.A.: sodium arachidonate (50 jaM);  C5-9: comple- 
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FIG.  3.  Effect of various  antibodies  on  arachidonate-mediated release of [14C]serotonin  in  the 
absence of exogenously added complement. A.A.: sodium arachidonate (70 pM); anti-HSA: anti- 
human serum albumin. In each case the F(ab')2 fragment of the antibody was utilized.  1 and 2 
indicate sequence of addition. 
pathway was required for the complement-dependent enhancement of arachidonate- 
mediated platelet release. 
Role of Platelet Membrane-bound Complement in the Absence of  Exogenously Added Complement 
Proteins.  Because complement components are present on the platelet surface (2), the 
possibility arose as to whether there is enough surface-bound complement to mediate 
the enhancement  effect in  the absence of exogenously added  protein.  To elucidate 
this point, washed platelets were incubated with various antibodies before exposure 
to sodium arachidonate.  No complement components were added,  As shown in Fig. 
3, the F(ab')2 fractions of anti-C3, anti-C4, and anti-human serum albumin caused no 
inhibition  of release of serotonin.  However, inhibition  was obtained if the platelets 
were  first  incubated  with  anti-C5  before exposure to  arachidonate.  Inhibition  was 
also obtained if the platelets were first incubated with anti-C6 or anti-C9 (data not 
shown).  Thus,  there  was sufficient  complement  proteins  on  the  platelet  surface to 262  COMPLEMENT  AND  ARACHIDONIC ACID TRANSFORMATION 
TA~I.E  II 
Amchidomc Acid-mediated Release of TXB2 in the Presence and Absence of 
Complement 
TXBz 
Experiment  Arachidonic  Arachidonic acid  Percent enhancement 
acid* alone  plus C5-9~ 
ng/ml 
1  51.9  90.7  74.7 
2  178.0  372.0  108.9 
3  52.1  154.0  195.5 
4  91.0  181.1  99.9 
* 70/~M arachidonic acid. 
~: 4 CH~0 U of each C5, C6, C7, C8, and C9. 
TABLE  III 
Arachidonate-mediated Uptake of C3 and C5 by Platelets 
Uptake mediated by 
Number of molecules//lg membrane 
protein 
C3  C5 
Sodium arachidonate (100 ~M)  None  3.06 x  I09 
support a  complement-mediated reaction in the absence of exogenously added com- 
plement components. 
Effect of Complement on Arachidonate-mediated Release of TXBz.  In every experiment, 
the addition of C5-C9 led to an increase in arachidonate-mediated release of TXB2. 
The enhancement  of release ranged from  74 to  195%  (Table II). 
Sodium Arachidonate-mediated Lysis of Washed Platelets.  It was  found  that  high  con- 
centrations  of sodium  arachidonate  (>100  /LM)  led  to  lysis of washed  platelets as 
determined by release of LDH.  This observation confirmed data published by Ts'ao 
and Holly (17). However, at concentrations of arachidonate of_<70 #M, <  10% release 
of LDH was obtained. In no case did addition of complement lead to an increase in 
release of LDH. 
Sodium Arachidonate-mediated Uptake of 1~I-C3  and 1z51-C5 by Platelets.  As shown  in 
Table III, incubation of platelet membranes with sodium arachidonate and comple- 
ment  components  C3-C9  in  which  either C3  or C5  was  labeled with  lz~I led to  a 
specific uptake of C5 of 3.06 ×  109 molecules//~g of membrane protein. The uptake of 
C3 was indistinguishable for that of the control sample lacking arachidonate. 
Morphological Demonstration of Arachidonate-Mediated Uptake of C5.  An indirect ferritin 
assay was utilized for this study. Platelets, following incubation with sodium arachi- 
donate  and  components  C3-C9,  were  first  incubated  with  the  F(ab')2 fractions  of 
either  anti-C3  or  anti-C5  and  subsequently  exposed  to  ferritin-conjugated  goat 
antibody to rabbit y-globulin. Fig. 4A demonstrates  the uptake and  distribution of 
the ferritin label when anti-C5 was employed. As shown in Fig. 4 B, no ferritin label 
was  present  when  the  antibody  employed  was  anti-C3.  These  data  thus  confirm 
morphologically that arachidonate-mediates uptake of C5, but not of C3. 
Physiocochemical and Morphological Demonstration of the Presence of C5b-9 Complexes on the M.  J.  POLLEY,  R.  L.  NACHMAN,  AND  B.  B.  WEKSLER  263 
Fro.  4.  Preparation  of platelet  membranes incubated with arachidonate and complement com- 
ponents  C3-C9  reacted  with  the  F(ab')z  fragment  of either  anti-C5  (A)  or  anti-C3  (B)  then 
subsequently with ferritin-conjugated goat anti-rabbit T-globulin. Unstained, X  198,000.  Arrows in 
(A) indicate typical clumps of ferritin molecules. No ferritin was seen in membrane preparation that 
had been reacted with anti-C3 (B). 264  COMPLEMENT  AND  ARACHIDONIC  ACID  TRANSFORMATION 
Fro.  5.  Electron microscopical analysis of 33S fraction from sucrose density gradient (see Materials 
and Methods). The sample was dialyzed to remove sucrose, stained with 2% sodium silicotungstate, 
and then applied directly to a  grid coated with collodion and carbon.  X  264,000. The micrograph 
illustrates a  suspension of C5b-9 dimers. The arrows indicate C5b-9 dimers which are settled flat 
on the grid. 
Platelet  Surface,  Their  Formation, and  Uptake Mediated  by  Sodium Arachidonate.  Platelet 
membranes were incubated with sodium arachidonate and complement components 
C5-C9  in  which  C5  was  radiolabeled.  The putative C5b-9  complexes were eluted 
with  10% DOC.  When the eluate was applied to a  Bio-Gel A15m column, complex 
formation was indicated by a peak of radiolabeled protein which eluted immediately 
after the position of a blue dextran marker. Material from this peak was subjected to 
sucrose  density  gradient  ultracentrifugation,  and  C5b-9  complex  formation  was 
indicated  by  the  presence of a  peak  of radiolabel  (125I-C5) with  a  sedimentation 
coefficient of 33S.  When  the  appropriate  fraction  from  the  density  gradient  was 
visualized under the electron microscope (Fig. 5), it was found to be morphologically 
identical  to the C5b-9  dimer previously reported  (18).  No complex formation was 
indicated in the control sample lacking arachidonate. 
Discussion 
This study was prompted by our earlier observations (2, 3) that thrombin-mediated 
platelet aggregation and release are significantly increased in the presence of comple- 
ment and that  the complement effect is inhibited by aspirin and indomethacin  (3). 
Because these drugs are known inhibitors of cyclo-oxygenase, this observation led us 
to postulate that the complement effect might be mediated via the arachidonic acid M. J.  POLLEY,  R.  L.  NACHMAN,  AND  B.  B.  WEKSLER 
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Fxa. 6.  ,Scheme showing the potential interrelations of the arachidonic acid transformation path- 
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transformation pathway. Thus, in this study, we attempted to elucidate the role of 
the complement system in this pathway. 
It was found that release of serotonin and TXB2 synthesis mediated by exogenous 
arachidonate was significantly enhanced in the presence of  complement. Only purified 
complement components C5, C6, C7, C8, and C9 were required for this reactivity. 
The demonstration of C5b-9 complexes in an eluate from platelet membranes that 
had interacted with arachidonic acid and complement further documents the partic- 
ipation of these proteins in the arachidonate-stimulated platelet response. No known 
activating mechanisms of the classical pathway or alternative pathway were required, 
nor was C3. Further, it was found that platelet-bound complement components play 
an essential role in modulating arachidonate-mediated sertonin release even in  the 
absence of exogenously added complement. 
It was of interest that  only complement components C5-9 were required for the 
enhancement effect of the arachidonic acid pathway. The complement enhancement 
of thrombin-mediated  platelet  function  requires  complement  components C3-C9, 
and  this effect is totally inhibited by aspirin  (3).  Assuming that  the metabolism of 
exogenous arachidonate is similar to that of the endogenous fatty acid released from 
cell  phospholipid,  the  possibility  exists  that  C3  in  association  with  thrombin  is 
required for mobilization of arachidonic acid from the phospholipid of the platelet 
membrane. Once the arachidonic acid is mobilized, C3 is no longer required, C5-C9 
being sufficient to modulate this pathway leading to enhanced production of TXB2. 
A scheme showing the potential interrelations of the arachidonic acid transformation 
pathway and the various complement components is shown in Fig. 6. A subject for 
further  study  is  to  determine  whether  C3  alone  is  required  for  mobilization  of 
endogenous arachidonic acid or whether C5-C9 are additionally required at this step. 
It is not known as yet how the assembly of C5b-9 complexes on the platelet surface 
can directly influence platelet function. The possibility exists that  the formation of 
the membrane attack complex (C5b-9) initiates a transmembrane signal that modu- 
lates the arachidonic acid transformation pathway leading to the increased production 
of TXB2. It is of some interest that the cyclo-oxygenase and thromboxane synthetase 
enzyme systems are located in different membrane compartments in the platelet (19). 
The  precise  molecular step  at  which  the  complement-mediated facilitation occurs 
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The functional physiologic significance of these findings in relation to the hemo- 
static process is best exemplified by the description of two recently reported patients, 
one deficient in C6,  the other in  C7  (20).  The C6-deficient patient  was  subject  to 
repeated  epistaxis.  This  patient's  platelets  in  platelet-rich  plasma  gave  reduced 
aggregation and serotonin release in response to thrombin when compared to normal 
platelets. Addition of purified C6 corrected the abnormality. The platelets of the C7- 
deficient patient also exhibited decreased thrombin-mediated aggregation, which was 
corrected by the addition of purified C7. Complement may play an important role in 
modulating  the  fine  tuning  of the  ptatelet  membrane  response  to  physiologically 
activating stimuli. 
To date, the facilitating role of complement on the arachidonic acid transformation 
pathway  has  been  studied  only in  platelets.  The  arachidonic  acid  transformation 
pathway plays a major role in influencing cellular behavior in other systems including 
endothelial cells  (21), basophils  (22), mast cells  (23,  24), polymorphonuclear leuko- 
cytes, and macrophages (25, 26) among others. It seems reasonable that complement 
components may also serve as regulatory modulators of arachidonic acid mobilization 
and transformation in these different cell systems. These potential relations remain a 
subject for further study. 
Summary 
Arachidonate-mediated  release of a4C  serotonin and  thromboxane B2  (TXB2)  is 
significantly enhanced  in  the  presence of complement.  Only  purified complement 
components C5,  C6,  C7,  C8,  and  C9  are  required  for this  reactivity.  No  known 
activating mechanism of the classical or alternative pathway is required, nor is C3. In 
the absence of exogenously added complement, platelet  membrane-bound comple- 
ment components play an essential role in modulating arachidonate-mediated sero- 
tonin release. Incubation of platelet membranes with arachidonate and C5-C9 led to 
the production of dimers of the membrane attack complex (C5b-9)  on the platelet 
surface. These macromolecular complexes were eluted from the platelet  membrane 
and were identified physicochemically and morphologically. 
The possibility arises that C3 in association with C5-C9 is required for mobilization 
of the arachidonic acid from the phospholipid of the platelet membrane.  Once the 
arachidonic acid is mobilized, C3  is no longer required, C5-C9 being sufficient to 
modulate this pathway leading to enhanced production of TXB2. 
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